在种族多样化城市人群中接受满意减瘤的晚期上皮性卵巢癌患者腹腔内化疗的应用:一家机构10年经验
本研究回顾性分析了2005至2016年间一家机构收治的96例接受初次肿瘤细胞减灭术的晚期上皮性卵巢癌患者,其中51%接受静脉/腹腔(IV/IP)化疗,49%接受静脉(IV)化疗。IV/IP化疗与更长的总生存期相关(中位76个月 vs 38个月,HR=0.31,95%CI 0.16-0.62,P<0.001)。作者认为需进一步研究以明确IV/IP化疗的使用障碍。
要点
- 在种族多样化城市人群中,约50%的满意减瘤晚期上皮性卵巢癌患者接受了IV/IP化疗。
- IV/IP化疗与仅静脉化疗相比,与更长的总生存期相关(中位76个月 vs 38个月)。
- 完成少于6周期IV/IP化疗的患者与完成6周期者相比,死亡风险有升高趋势(HR=3.2,95%CI 0.98-9.27,P=0.05)。
核心结论
- 在种族多样化的城市患者中,50%接受了IV/IP化疗,且与仅静脉化疗相比与改善的总生存期相关。
- 需要进一步研究以明确使用IV/IP化疗的障碍。
研究设计与样本
- 回顾性研究,经IRB批准,纳入2005至2016年在本机构接受初次肿瘤细胞减灭术的上皮性卵巢癌患者。
- 共纳入96例晚期满意减瘤的上皮性卵巢癌患者,中位随访33个月。
- 接受至少一个IV/IP周期的患者归入IV/IP队列,采用Kaplan-Meier和Cox比例风险模型进行分析。
- 死亡通过国家社会保障死亡索引核实。
主要发现
- 51%的患者接受IV/IP化疗,49%接受IV化疗。
- 患者种族分布为白人27%、黑人22%、其他种族39%。
- 与仅静脉化疗相比,IV/IP化疗与更长的总生存期相关(log rank P<0.002)。
- IV/IP化疗与仅静脉化疗相比,与较低的死亡风险相关(HR=0.31,95%CI 0.16-0.62,P<0.001)。
- IV/IP组和IV组的中位总生存期分别为76个月(95%CI 62-未估计)和38个月(95%CI 30-55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The goal of our study was to define utilization and clinical results of intraperitoneal (IV/IP) compared to intravenous (IV) chemotherapy in a racially and ethnically diverse population with optimally debulked advanced stage epithelial ovarian cancer. METHODS: After IRB approval, all patients diagnosed with epithelial ovarian cancer that underwent primary cytoreductive surgery at our institution from 2005 to 2016 were identified. Death was verified by the National Social Security Death Index. Patients who received at least one IV/IP cycle were analyzed in the IV/IP cohort. Kaplan-Meier and Cox proportional hazards models were performed. RESULTS: 96 patients with advanced stage optimally cytoreduced epithelial ovarian cancer (median follow up 33months) were identified. 51% and 49% of patients received IV/IP and IV chemotherapy, respectively. 27%, 22%, and 39% of patients were of white, black, and other race. Compared with IV chemotherapy only, IV/IP chemotherapy was associated with longer OS (log rank <0.002) and IV/IP chemotherapy versus IV chemotherapy alone was associated with a lower risk of death (HR=0.31, 95% CI 0.16-0.62, P<0.001). The median overall survival for the IV/IP and IV groups was 76months (95% CI 62 - not estimated) and 38months (95% CI 30-55), respectively. There was a trend toward higher risk of death for patients who completed fewer than 6cycles of IV/IP chemotherapy compared to women who completed 6 IV/IP cycles (HR=3.2, 95% CI 0.98-9.27 (P=0.05). No differences in patient or tumor characteristics were identified between these two groups of patients. CONCLUSIONS: In our racially diverse urban patients, 50% of patients received IV/IP chemotherapy and it was associated with improved overall survival compared to IV chemotherapy alone. Further investigation is needed to identify barriers to use of IV/IP chemotherapy.
引用
- Miller EM, Tymon-Rosario J, Xie X, et al. Utilization of intraperitoneal chemotherapy for optimally cytoreduced advanced stage epithelial ovarian cancer: A 10-year single institution experience with a racially diverse urban population. Gynecol Oncol. 2017. PMID: 28751119. doi:10.1016/j.ygyno.2017.07.129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。